IOVA

6.9005.61%
FG

Frederick G. Vogt

Interim CEO, President, General Counsel, Corporate Secretary & Director

Dr. Frederick G. Vogt, PhD, Esq., JD, serves as an Interim CEO & President at Iovance Biotherapeutics, Inc. since June 10, 2021 and is its Director since June 11, 2024. He has been the General Counsel at Iovance Biotherapeutics, Inc. since July 1, 2017 and has been its Corporate Secretary. Dr. Vogt joined Iovance Biotherapeutics, Inc. in September 30, 2016 and served as its Vice President of Intellectual Property. He has a wide experience in the pharmaceutical and biopharmaceutical industries. Prior to joining Iovance Biotherapeutics, Inc., he practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional and litigation matters. Previously he served in numerous scientific, management and legal roles of increasing responsibility at GlaxoSmithKline, where he focused primarily on oncology and cardiovascular drug development. He admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office and the U.S. District Court for the Eastern District of Pennsylvania. Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania State University and a J.D. from Temple University.

Positions